News

Nexalin Technology (NXL), announced the completion and launch of phases one through five of its proprietary virtual clinic and digital research ...
This milestone builds upon phase one of the virtual clinic ... we can now facilitate clinical research on the HALO™ device while preparing for broader patient adoption. By creating a seamless ...
Stablepharma Ltd is a high-growth biotechnology company based in the UK and Spain, with the mission to reduce reliance on the ...
CERo Therapeutics Holdings, Inc. has announced that the Sarah Cannon Research Institute at the Colorado Blood Cancer Institute will be a key clinical trial site for its Phase 1 trial of CER-1236 ...
core cohort dose-limiting toxicity observation period in its ongoing Phase 1b/2a clinical trial. Following a review of safety and efficacy data, the Safety Review Committee (SRC) has approved dose ...